• Skip to main content

  • Home
  • News
    • New Funds
    • New Financings
    • People On the Move
    • Trends and Strategies
  • Transactions
    • New Platforms
    • New Add Ons
    • New Exits
  • Briefly
  • 2025 Salary Survey
  • Member Center
Please enter your username/email.
Please enter your password.
Login
Something went wrong. Please check your entries and try again.
PEP-logo-v9
Flag-small-6-28-24-120x73

January 13, 2026

Private equity's news leader since 2007

Chicago, Illinois

pep-superman-header-80x105-1

"There is a right and a wrong in the universe, and that distinction is not hard to make."

Superman

  • About Us
  • Membership
  • Webinars
  • Store
  • FAQs
  • Advertise With Us
  • Contact Us
Search

pharma contract developer

Nautic Acquires Mikart

September 27, 2018 by John McNulty

Nautic Partners has acquired Mikart, a contract developer and manufacturer of solid dose and non-sterile liquid pharmaceuticals.

Mikart’s services include formulation development, clinical trial supplies, regulatory filing support, analytical services, clinical manufacturing, commercial manufacturing, and packaging. The company can manufacture products in tablet, capsule, or liquid form and its packaging capabilities include bottle filling, blister packaging, pouch and foil strip packs, and cartoning and tray packaging.

Mikart has 234,000 sq. ft. of facilities in Atlanta that meet and exceed current FDA and cGMP standards. The company was founded in 1975 and is headquartered in Atlanta (www.mikart.com).

“In Nautic, Mikart has found the ideal partner to continue scaling the business while staying true to its customer-focused roots,” said retiring owner Miguel Arteche. “Nautic offers a compelling combination of healthcare, manufacturing and financial experience to help Mikart thrive and expand within the rapidly growing contract development and manufacturing market.”

“We are excited to partner with Mikart given their strong competitive position, high record of quality, and great company culture,” said Chris Crosby, a Managing Director of Nautic.

At closing of the acquisition, Nautic appointed Michael Kallelis as the new CEO of Mikart. Mr. Kallelis has over 30 years of experience with public and private life sciences companies. Most recently, from July 2013 to August 2018, he was Vice President of Business Development, at KMC Systems, and earlier he was Chief Operating Officer and co-founder of Boston BioSystems, an active pharmaceutical ingredient (API) contract manufacturing company. Mr. Kallelis was also President and Chief Operating Officer at Exiqon, a gene expression analysis company, which he helped take public in 2007. He has also held senior roles at GE Life Sciences and Millipore. “The work Miguel and Mikart’s management team have done to develop Mikart’s premier brand status in the market and strong reputation amongst customers is impressive,” said Mr. Kallelis. “We hope to build off this foundation and partner with existing and future clients to fill their CDMO needs.”

“We look forward to helping Mikart increase customer awareness of its compelling offerings and manufacturing excellence, as well as supporting Mike and the company in various growth initiatives,” said Chris Vinciguerra, a Principal of Nautic.

Nautic Partners is a middle-market private equity firm with over $2.5 billion of equity capital under management. Nautic targets majority equity investments of $25 million to $75 million. Sectors of interest include business services, manufacturing, and healthcare. The firm was founded in 1986 and is headquartered in Providence, RI (www.nautic.com).

© 2018 Private Equity Professional | September 27, 2018

Filed Under: New Platform, Transactions Tagged With: pharma contract developer

PEP_mainlogo_White

Private Equity Professional
c/o Sun Business Media
PO Box 6610
Evanston, Illinois 60204
Office Direct (847) 920-8010

[email protected]

News

  • Platforms
  • Add Ons
  • Exits
  • Funds
  • Financings
  • People
  • Strategies

Customer Help

  • Why Advertise?
  • PEP Media Kit

Memberships

  • Individual

Advertising

  • Why Advertise?
  • PEP Media Kit

© 2026 Private Equity Professional. All Rights Reserved.